Table 3.

Serious adverse events in patients treated with lorlatinib (reported in >1% of patients)

	N = 80, n (%)
	Grade 3-5	Grade 3	Grade 4	Grade 5
Any adverse event	26 (33)	15 (19)	11 (14)	0 (0)
Hypercholesterolemia	10 (13)	6 (8)	4 (5)	0 (0)
Cognitive effect	6 (8)	5 (6)	1 (1)	0 (0)
Hypertriglyceridemia	4 (5)	1 (1)	3 (4)	0 (0)
Mood effect	3 (4)	2 (3)	1 (1)	0 (0)
Peripheral neuropathy	2 (3)	2 (3)	0 (0)	0 (0)
Renal failure	2 (3)	1 (1)	1 (1)	0 (0)
Edema	1 (1)	1 (1)	0 (0)	0 (0)
Fatigue	1 (1)	1 (1)	0 (0)	0 (0)
Arthralgia	1 (1)	1 (1)	0 (0)	0 (0)
Pulmonary hypertension	1 (1)	0 (0)	1 (1)	0 (0)
Interstitial lung disease	1 (1)	0 (0)	1 (1)	0 (0)
Abdominal pain	1 (1)	1 (1)	0 (0)	0 (0)
Amylase increase	1 (1)	1 (1)	0 (0)	0 (0)
Cholestasis	1 (1)	1 (1)	0 (0)	0 (0)